Close Menu
Eye On IVD
  • Contact
  • About

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

What's Hot

In Vitro Diagnostics Stocks, 2025 Flu Season, Diasorin Reports

May 7, 2025

Clinical Laboratory Market Nears $400 Billion: Report

April 22, 2025

“It Just Wreaks Havoc” – Webinar Debates Tariff Impact on IVD, LDT Rule Vacation, Other Topics

April 4, 2025
Facebook X (Twitter) Instagram
LinkedIn
Eye On IVDEye On IVD
Subscribe
  • Home
  • Research report shop
  • IVD NEWS
  • Contact Us
  • About Us
Eye On IVD
Home»Media & Culture»In Vitro Diagnostics: Cautious Optimism in the 1Qs
Media & Culture

In Vitro Diagnostics: Cautious Optimism in the 1Qs

Bruce CarlsonBy Bruce CarlsonJuly 13, 2024Updated:August 4, 2024No Comments4 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

Inspecting the first quarter of 2024 in vitro diagnostic results, we may be getting to growth without the “ifs, ands, or buts.” Four years out from the pandemic, that is a reasonable goal.

What do we mean by that? IVD test markets – markets for chemistries, critical care, infectious disease tests, cancer tests, have always been growing, even through the pandemic. This is a time of aging populations and healthcare expansion around the world. COVID-19 revenues were seen in such large numbers that they then depressed revenue growth later. So companies adjusted, offering explained results. “core revenues are up” etc. But eventually, one expects growth in in vitro diagnostic revenues without having to mention “we are growing in our core areas,” or “excluding COVID-19.” Even though it was fair to make those distinctions in the post-Omicron revenue drop. Investors needed to be told that the industry was selling a lot of cardiac markers while sales of home tests might be dropping.

Now a few firms have halted the decline in overall revenues. Take Roche, which now has 2 quarters of positive “no ifs, ands, or buts” growth.

We start with Roche, as per the chart below has recovered from the big growth decline. “2024 is the last year we expect COVID impact on our year-over-year performance,” said Matt Sause, CEO of Roche Diagnostics in Roche’s recent Q1 earnings call. Not only is the firm showing greater, but they had installed-based gains last year in most instruments and had new products to discuss, a malaria test, a respiratory panel, TBI, and other items.

The chart below, of Roche’s reported overall growth rate provides a visual on that change, 1Q 2024 is the second positive growth since the general decline of COVID testing in Q2 2022.

While Roche’s core (non-COVID) business has always grown during this period, now the overall business is.

As Roche goes IVD?

Not exactly – it is necessary to look at other companies to call a trend because Roche’s growth might come at the expense of other concerns. Abbott, for instance, is highly dependent on COVID-19 revenue having been the leader during the pandemic. In their Q1, they report revenues 17% down from the previous quarter, but up 5.4% with COVID-19 excluded. (I’ll add that with glucose considered, the company in all testing products, is highly competitive).

bioMérieux

Yet take a look at French infectious disease specialist bioMérieux. The company’s BIOFIRE business, reflected in its Molecular Biology segment, is extremely healthy, with high double-digit growth.

biomerieux results 1Q

Overall, they are up 11% from 2023 first quarter. Immunoassays are down a bit, which is COVID-19 impacted. (they also believe some overpurchasing by labs in previous quarters settling out).

If we look at Siemens Healthineers, Q1 2024 pulled in less revenue than Q1 2023, but only 3% less. Down but recoverable, I think.

Siemens Healthineers Diagnostic Division 1Q 2024

Considering the cautious optimism in the 1Qs, the predictions made by many analysts in 2020 may be true:

Within a five-year forecast from the COVID-19 pandemic, the rest of IVD would make up for the COVID-19 crest and replace those revenues.

Bold in 2020. Now, seems about right. We are on the track, and a few longer-term trends are originating from the pandemic such as molecular system expansion, automation, respiratory panels, and, sadly for the little guys – increased consolidation of both labs and IVDs. As we go into the ADLM conference end of this month, EYE ON IVD will be reporting on where we stand on all of those trends.

399 Subscribers, waiting for that 400th!!

Please tell someone else if you think they may benefit from this newsletter.

Note that EYE ON IVD will be at ADLM (former AACC) – thanks to the press staff for allowing us the opportunity.


Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Bruce Carlson
  • Website

Related Posts

Attendance at ADLM Chicago Soars to 18,000, NGS in Routine Micro, Fast Pediatric Kidney Injury Detection, and LDTs

August 3, 2024

ADLM Takes On FDA LDT Rule, With a Little Help From Friends. Also Automatic Blood Draws and DNA Passports? Notes – 7/31

August 2, 2024

“You’ve Been Speeding All Along, You Just Didn’t Know it” ADLM Webinar on New LDT Rule

June 26, 2024
Leave A Reply Cancel Reply

THE LATEST

MARKET INTELLIGENCE Demo

DON'T MISS

Clinical Laboratory Market Nears $400 Billion: Report

April 22, 2025

Growth, But Not Huge Growth: A Look at Q3 Revenue Results at IVD Companies

October 24, 2024

Attendance at ADLM Chicago Soars to 18,000, NGS in Routine Micro, Fast Pediatric Kidney Injury Detection, and LDTs

August 3, 2024
Stay In Touch
  • Twitter
  • LinkedIn
Don't Miss

In Vitro Diagnostics Stocks, 2025 Flu Season, Diasorin Reports

Uncategorized May 7, 2025

How are IVD stocks doing in the general market fall? About that huge flu season.…

Clinical Laboratory Market Nears $400 Billion: Report

April 22, 2025

“It Just Wreaks Havoc” – Webinar Debates Tariff Impact on IVD, LDT Rule Vacation, Other Topics

April 4, 2025

Sepsis Report Details Unique IVD Market Strategy

April 2, 2025

Subscribe to EYE ON IVD

Get the latest news about the in vitro diagnostics market, from the experts.

Eye On IVD
LinkedIn
  • Home
  • Research Report Shop
  • About
  • Contact
  • Subscribe
Copyright © 2024 Eye On IVD LLC. All Rights Reserved

Type above and press Enter to search. Press Esc to cancel.